TAS::75 0849::TAS SBIR TOPIC 277 - DEVELOPMENT OF A CLINICAL DIAGNOSTIC ASSAY FOR ALK INHIBITOR RESISTANCE MUTATIONS

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$193,637.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
N43CO110110
Agency Tracking Number:
N43CO110110
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
INSIGHT GENETICS, INC.
111 10TH AVE S STE 110, NASHVILLE, TN, 37203-3843
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
999999999
Principal Investigator
 DAVID HOUT
 (858) 549-9431
 DHOUT@INSIGHTGENETICSINC.COM
Business Contact
 DAVID HOUT
Phone: (858) 549-9431
Email: DHOUT@INSIGHTGENETICSINC.COM
Research Institution
 Stub
Abstract
Kinase inhibitors have revolutionized cancer treatment but their use has led to drug resistance, prompting development of follow-on inhibitors for resistant tumors. Anaplastic lymphoma kinase (ALK) was discovered by Dr. Stephan Morris (Insight Genetics collaborator on these studies). ALK fusion genes and activating point mutations cause several cancers, and multiple pharmaceutical firms are developing ALK inhibitors. One inhibitor PF-02341066 (crizotinib, Pfizer) has entered Phase III trials and will likely receive FDA approval in 2011. The Morris group has identified a large number of ALK kinase domain mutations that confer high-level PF-02341066 resistance, which has already been reported in patients. A clinical genetic test to identify inhibitor-resistance mutations is needed to guide the development and use of next-generation ALK inhibitors for patients resistant to 1st-generation therapy. The work proposed herein will develop a clinical diagnostic assay for ALK inhibitor-resistance mutations to address this unmet need. Objective 1. Development and application of a genetic diagnostic assay to detect all known ALK inhibitor-resistance mutations using an allele-specific PCR platform. Objective 2: Demonstration and validation of the ability of the test to identify ALK mutations from both cell lines with ALK inhibitor resistance and re-biopsied lung cancer specimens from patients who developed PF-02341066 resistance.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government